In response to: Multiple assays in a real-time RT-PCR severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) panel can mitigate the risk of loss of sensitivity by new genomic variants during the COVID-19 outbreak
Luis Peñarrubia,
Maria Ruiz,
Roberto Porco,
Sonia N. Rao,
Stephen A. Vella,
Martí Juanola-Falgarona,
Davide Manissero,
Marta López-Fontanals,
Josep Pareja
Affiliations
Luis Peñarrubia
STAT-Dx Life, S.L. (a QIAGEN Company), Barcelona, Spain
Maria Ruiz
STAT-Dx Life, S.L. (a QIAGEN Company), Barcelona, Spain
Roberto Porco
STAT-Dx Life, S.L. (a QIAGEN Company), Barcelona, Spain
Sonia N. Rao
QIAGEN, Inc., Germantown, MD, USA
Stephen A. Vella
QIAGEN, Inc., Germantown, MD, USA
Martí Juanola-Falgarona
STAT-Dx Life, S.L. (a QIAGEN Company), Barcelona, Spain
Davide Manissero
QIAGEN Manchester Ltd, Manchester, UK
Marta López-Fontanals
STAT-Dx Life, S.L. (a QIAGEN Company), Barcelona, Spain
Josep Pareja
Corresponding author.; STAT-Dx Life, S.L. (a QIAGEN Company), Barcelona, Spain
